Regorafenib to help prevent cancer return after treatment
Part of Bones, joints & muscles, Cancer clinical trials.
This Phase 2 study tests whether regorafenib, given after your main treatments, can help keep high-grade bone sarcoma from coming back or progressing. It checks safety and whether this “maintenance” approach works better than best supportive care alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 12 years old when you sign consent.
- Your bone cancer is a high-grade bone sarcoma confirmed by biopsy (for example osteosarcoma or Ewing sarcoma).
- There is measurable remaining cancer that cannot be removed by surgery, either at diagnosis or after relapse.
- Your cancer is not getting worse at the start of the study, based on the study’s scan rules.
- You finished your last cancer treatment (chemo or surgery) at least 4 weeks ago, but no more than 2 months ago.
- Your blood counts and organ tests (liver, kidney, and pancreas) must be within required limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether regorafenib given after first treatment helps patients with bone sarcoma stay in remission longer. It focuses on safety and whether the medicine can prevent the cancer from growing or returning.
This study tests two treatments for high-risk osteosarcoma (a bone cancer). It compares mifamurtide plus standard treatment versus sorafenib plus standard treatment to see which is safer and more effective.
This Phase 2 trial studies HS-20093 in adults with osteosarcoma or other sarcomas that came back or did not respond to standard treatment. It aims to see how well the drug works and whether it is safe for people whose cancer has progressed.
This trial tests a pill called sulfatinib for young people with bone cancer (osteosarcoma) that has come back or not responded to standard treatments. Sulfatinib works by cutting off the blood supply that tumors need to grow, and the goal is to see if it can control the cancer.
This study tests a combination of two drugs, cabozantinib and ifosfamide, for sarcomas that have come back or not responded to treatment. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of two drugs, losartan and sunitinib, in people with osteosarcoma that has come back or spread after prior treatment. The study aims to see if this combination is safe and effective.
Hear when a new Bone Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.